PD-1 and PD-L1 Inhibitors Market Size, Share, Growth Analysis, By Product (Nivolumab, Pembrolizumab), By Indication (Melanoma, Non-Small Cell Lung Cancer (NSCLC)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region - Industry Forecast 2025-2032

North America is one of the largest markets for PD-1 and PD-L1 inhibitors, and it is expected to dominate the global market during the forecast period. The region's dominance can be attributed to various factors such as the high prevalence of cancer and autoimmune diseases, the presence of key market players, and favorable reimbursement policies. In North America, the United States holds the largest share of the PD-1 and PD-L1 inhibitors market, owing to the high prevalence of cancer and autoimmune diseases in the country. According to the American Cancer Society, it is estimated that in 2022, there will be around 1.9 million new cancer cases and over 609,000 cancer deaths in the United States. The rising incidence of cancer in the country is expected to drive the demand for PD-1 and PD-L1 inhibitors. Moreover, the presence of key market players in the region is also expected to drive the growth of the PD-1 and PD-L1 inhibitors market. Some of the major players in the market, such as Bristol-Myers Squibb, Merck & Co., and Pfizer, have their headquarters in the United States. These players are investing heavily in research and development activities to develop innovative PD-1 and PD-L1 inhibitors for the treatment of various diseases. Additionally, favorable reimbursement policies in the region are also expected to drive the growth of the market. The Affordable Care Act (ACA) in the United States has made it mandatory for insurers to cover cancer treatment costs, including PD-1 and PD-L1 inhibitors, which has increased patient access to these drugs.

On the other hand, Asia-Pacific (APAC) is expected to be the fastest growing region in the global PD-1/PD-L1 inhibitors market, owing to the increasing prevalence of cancer in the region and the growing adoption of immunotherapy. The region has a large population, which has led to a high burden of cancer, particularly in countries such as China, Japan, and South Korea. In addition, the region has witnessed significant investments in healthcare infrastructure, which has further propelled the growth of the market. Governments in the region have also implemented favorable policies to promote the adoption of immunotherapy, such as the inclusion of PD-1/PD-L1 inhibitors in the national healthcare reimbursement schemes. Moreover, the increasing focus on research and development activities, particularly in countries such as China and India, is expected to further drive the growth of the market. These countries have large populations and significant resources, which has led to the emergence of a strong research and development ecosystem. Key players in the market are also focusing on expanding their presence in the region by entering into partnerships and collaborations with local companies. For instance, Bristol-Myers Squibb entered into a collaboration with China's CSPC Pharmaceutical Group Limited to develop and commercialize its PD-1 inhibitor drug in China.